NS Pharma, Inc. (NS Pharma), a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced today that the U.S. Food and Drug Administration has accepted for review the Biologics License ...

But more hauntingly, it is the story of how Hurti fell, dragging into its rubble, Saltifat and Justice Mangut, and a host of ...

The clinical, cardiovascular and neuroendocrine profile of ampreloxetine showed target engagement of residual peripheral autonomic neurons and a sustained standing blood pressure effect, which is ...

At the turn of the last century, an inventor had a revelation. Inspired by the cinematic pioneering of the Lumière brothers, ...

Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

There is still one Nightwing story arc that DC has yet to deliver, and fans are more than a little desperate to see it. Will ...

YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 TRELEGY net sales of $854M, as reported by GSK, increased ...

President Trump recently signed a wide-ranging executive order urging Congress to amend a crucial provision of a Biden-era ...

Almost nothing about Shia LaBeouf‘s involvement with Orphans went the right way ... and my desperate need to show him all my prep, or that he would accept me somehow. I was so insecure.

It is also why rare-disease treatments are considered “pharmaceutical orphans,” as they are often left without sufficient support or investment, or abandoned altogether. Hence the moniker ...

With clinics shutting down and orphanages filling up, Christian health workers worry about worsening health outcomes in ...